The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver.
Open accessAbstract
In vitro studies with human liver indicate that the major catalyst involved in the bioactivation of the hepato-carcinogen aflatoxin B1 (AFB1) to its genotoxic 2,3-epoxide derivative is cytochrome P-450NF (P-450NF), a previously characterized protein that also catalyzes the oxidation of nifedipine and other dihydropyridines, quinidine, macrolide antibiotics, various steroids, and other compounds. Evidence was obtained using activation of AFB1 as monitored by umuC gene expression response in Salmonella typhimurium TA1535/pSK1002 and enzyme reconstitution, immunochemical inhibition, correlation of response with levels of P-450NF and nifedipine oxidase activity in different liver samples, stimulation of activity by 7,8-benzoflavone, and inhibition of activity by troleandomycin. Similar results were obtained when levels of 2,3-dihydro-2-(N7-guanyl)-3-hydroxyaflatoxin B1 formed in DNA were measured. P-450NF or a closely related protein also appears to be the major catalyst involved in the activation of aflatoxin G1 and sterigmatocystin, the latter compound being more genotoxic than AFB1 in these systems. Several drugs and conditions are known to influence the levels and activity of P-450NF in human liver, and the activity of the enzyme can be estimated by noninvasive assays. These findings provide a test system for the hypothesis that a specific human disease state (liver cancer) is linked to the level of oxidative metabolism in populations in which aflatoxin ingestion is high.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Experiments in molecular genetics
Miller, J. H. (1972) · Medical Entomology and Zoology · Cited by 27,157
Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals.
McCann, J., Choi, E., Yamasaki, E., & Ames, B. N. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.12.5135 · Cited by 3,323
Guengerich, F. P., Dannan, G. A., Wright, S. T., Martin, M. V., & Kaminsky, L. S. (1982) · Biochemistry · doi:10.1021/bi00266a045 · Cited by 1,012
Self-citationThe P450 Gene Superfamily: Recommended Nomenclature
NEBERT, D. W., ADESNIK, M., COON, M. J., ESTABROOK, R. W., GONZALEZ, F. J., GUENGERICH, F. P., GUNSALUS, I. C., JOHNSON, E. F., KEMPER, B., LEVIN, W., et al. (1987) · DNA · doi:10.1089/dna.1987.6.1 · Cited by 818
Self-citationGuengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., & Waxman, D. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)89213-x · Cited by 724
Self-citationEvaluation of the new system (umu-test) for the detection of environmental mutagens and carcinogens
Oda, Y., Nakamura, S.-I., Oki, I., Kato, T., & Shinagawa, H. (1985) · Mutation Research/Environmental Mutagenesis and Related Subjects · doi:10.1016/0165-1161(85)90062-7 · Cited by 631
Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy.
Guengerich, F. P. (1988) · PubMed · Cited by 455
Self-citationWaxman, D. J., Attisano, C., Guengerich, F. P., & Lapenson, D. P. (1988) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(88)90655-8 · Cited by 414
Self-citationMetabolic oxidation phenotypes as markers for susceptibility to lung cancer
Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., & Hetzel, M. R. (1984) · Nature · doi:10.1038/312169a0 · Cited by 383
Distlerath, L. M., Reilly, P. E., Martin, M. V., Davis, G. G., Wilkinson, G. R., & Guengerich, F. P. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39456-5 · Cited by 319
Self-citationIdentification of an inducible form of cytochrome P-450 in human liver.
Watkins, P. B., Wrighton, S. A., Maurel, P., Schuetz, E. G., Mendez-Picon, G., Parker, G. A., & Guzelian, P. S. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.18.6310 · Cited by 317
Oxidation of quinidine by human liver cytochrome P-450.
Guengerich, F. P., Müller-Enoch, D., & Blair, I. A. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10372-6 · Cited by 304
Self-citationBuening, M. K., Chang, R. L., Huang, M., Fortner, J. G., Wood, A. W., & Conney, A. H. (1981) · PubMed · Cited by 287
Shimada, T., Misono, K. S., & Guengerich, F. P. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36183-5 · Cited by 256
Self-citationOxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450.
Guengerich, F. P. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13356-7 · Cited by 237
Self-citationOhnhaus, E. E., & Park, B. K. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00609878 · Cited by 183
Groopman, J. D., Donahue, P. R., Zhu, J. Q., Chen, J. S., & Wogan, G. N. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6492 · Cited by 181
Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man
Kleinbloesem, C. H., van Brummelen, P., Faber, H., Danhof, M., Vermeulen, N. P. E., & Breimer, D. D. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90165-5 · Cited by 181
SCHWAB, G. E., Raucy, J. L., & Johnson, E. F. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13354-3 · Cited by 169
Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T., & Kanakubo, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)76460-6 · Cited by 162
Beaune, P. H., Umbenhauer, D. R., Bork, R. W., Lloyd, R. S., & Guengerich, F. P. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.21.8064 · Cited by 158
Self-citationKaisary, A., Smith, P. J., Jaczq, E., et al. (1987) · PubMed · Cited by 147
Wolff, T., Distlerath, L. M., Worthington, M., Groopman, J. D., Hammons, G., Kadlubar, F. F., Prough, R. A., Martin, M. V., & Guengerich, F. P. (1985) · PubMed · Cited by 124
Self-citationHuang, M., Johnson, E. F., Müller‐Eberhard, U., Koop, D. R., Coon, M. J., & Conney, A. H. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68529-7 · Cited by 120
Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj
Wrighton, S. A., Thomas, P. E., Ryan, D. E., & Levin, W. (1987) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(87)90347-x · Cited by 111
Pessayre, D., Descatoire, V., Konstantinova-Mitcheva, M., Wandscheer, J.-C., Cobert, B., Level, R., Benhamou, J., Jaouen, M., & Mansuy, D. (1981) · Biochemical Pharmacology · doi:10.1016/0006-2952(81)90125-8 · Cited by 100
Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects
Schellens, J. H. M., Soons, P. A., & Breimer, D. D. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90238-9 · Cited by 92
Tsutomu, S., & Sei-ichi, N. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90497-7 · Cited by 77
Cited by
CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism
Guengerich, F. P. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.1 · Cited by 1,267
Self-citationShimada, T., & Fujii‐Kuriyama, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03162.x · Cited by 804
Self-citationGuengerich, F. P. (1995) · Cytochrome P450 · doi:10.1007/978-1-4757-2391-5_14 · Cited by 728
Self-citationMolecular Basis of Ethnic Differences in Drug Disposition and Response
Xie, H.-G., Kim, R. B., Wood, A. J., & Stein, C. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.815 · Cited by 600
Cytochrome P450 3A: Ontogeny and Drug Disposition
de Wildt, S. N., Kearns, G. L., Leeder, J. S., & van den Anker, J. N. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937060-00004 · Cited by 586
Metadata
- Authors
- Shimada, T., & Guengerich, F. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1989-01
- Volume
- 86
- Issue
- 2
- Pages
- 462-465
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1985866882
- Cited by
- 299
- References
- 28
- FWCI
- 20.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.